Corringham R, Gilmore M, Prentice H G, Boesen E
Cancer. 1983 Nov 15;52(10):1783-7. doi: 10.1002/1097-0142(19831115)52:10<1783::aid-cncr2820521004>3.0.co;2-h.
Seventeen patients were treated with high-dose melphalan with autologous bone marrow transplant (ABMT) and cyclophosphamide pretreatment. All of the patients had marrow reconstitution. Although there was one death caused by infection, high-dose melphalan with ABMT causes toxicity that is generally acceptable, and can achieve a high-response rate, but with responses of short duration in tumors resistant to standard-dose combination chemotherapy. In other poor-prognosis tumors that are sensitive to chemotherapy, or can be debulked surgically, or locally irradiated, high-dose melphalan with ABMT given as late intensification therapy may significantly prolong time to relapse, and ultimately prolong survival.
17例患者接受了大剂量美法仑联合自体骨髓移植（ABMT）及环磷酰胺预处理。所有患者均实现了骨髓重建。尽管有1例患者死于感染，但大剂量美法仑联合ABMT引起的毒性通常是可接受的，且可实现高缓解率，但对于对标准剂量联合化疗耐药的肿瘤，缓解持续时间较短。在其他对化疗敏感、可通过手术减瘤或局部放疗的预后不良肿瘤中，作为晚期强化治疗给予大剂量美法仑联合ABMT可能会显著延长复发时间，并最终延长生存期。
